/PRNewswire/ Health Canada recently authorized the Dolphin Vagal Nerve Stimulator by the Center for Pain and Stress Research to treat symptoms in patients.
/PRNewswire/ Health Canada recently authorized the Dolphin Vagal Nerve Stimulator by the Center for Pain and Stress Research to treat symptoms in patients.
, Feb. 9, 2021 /PRNewswire/
Health Canada has approved Bactiguard s urinary catheter with temperature sensor for infection prevention through an Interim Order. The approval is driven by COVID-19, as Bactiguard s catheters can reduce the risk of secondary infections for critically ill patients. Many critically ill COVID-19 patients require a urinary catheter with integrated temperature monitoring. The ICU treatment period can be 14 days or more, which means patients will require an indwelling urinary catheter for a long period of time. Each day with a catheter increases the risk of acquiring catheter-associated urinary tract infection (CAUTI) and any secondary bacterial infection in these patients could worsen an already serious condition. With Bactiguard s catheter, this risk is significantly reduced , says Dr. Stefan Grass, Chief Medical Officer and deputy CEO at Bactiguard.
In other industry news of note:
Mydecine Innovations Group (CSE:MYCO) (MYCO.CNQ), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, recently announced that it has partnered with ProPharma Group, the leading provider of regulatory and compliance services to the pharmaceutical, biotech, and medical device industries. As part of the agreement, ProPharma Group will provide regulatory advisement as the company seeks approval from the Food and Drug Administration (FDA) for its drug development platform as well as the Company s various stage clinical trials. ProPharma Group is a globally recognized firm with a strong track record of working with life sciences and biopharma companies to ensure full compliance with all FDA regulations, including all necessary steps for eventual global federal approvals, said Josh Bartch, CEO and Co-Founder of Mydecine. Mydecine cur